Damon E. Houghton

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher et al. · Journal of Thrombosis and Haemostasis · 2019 · 554 citations

Thrombosis, Venous Thrombosis, Adam Vte Trial +6

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing

Saskia Middeldorp, Robby Nieuwlaat, Lisa Baumann Kreuziger et al. · Blood Advances · 2023 · 195 citations · Full text

Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer‐associated venous thromboembolism

Waldemar E. Wysokiński, Damon E. Houghton, Ana I. Casanegra et al. · American Journal of Hematology · 2019 · 72 citations · Full text

Recurrent Vte, Pharmacotherapy, Logistic Analysis +19

Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients

Rahul Chaudhary, Jalaj Garg, Damon E. Houghton et al. · Mayo Clinic Proceedings Innovations Quality & Outcomes · 2021 · 71 citations · Full text

Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial

Robert D. McBane, Charles L. Loprinzi, Tyler Zemla et al. · Journal of Thrombosis and Haemostasis · 2024 · 49 citations · Full text

Thrombosis, Venous Disease, Oncology +8